A new microscopy technique (LM-method) developed to detect Lyme disease is unable to distinguish infected patients from healthy controls, yielding false-positive results that could lead doctors to over-diagnose a patient, according to new research published in the journal Infectious Diseases .
The new research follows up on a previous study suggesting that modified microscopy techniques (LM-method) could detect active cases of Lyme disease (caused by Borrelia bacteria) and Babesia (a tick-borne malaria-like parasite) in just one to two days. Despite considerable publicity and patient demand for this test in Norway, earlier studies did not include a control group and methods were not validated and ready for use in patients. read more
Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance New partners are joining founding members Merck, Illumina and Genea to support standardization of processes in assisted reproductive treatment laboratories Update on the alliance’s activities to be presented at ESHRE
Darmstadt, Germany, June 30, 2016 – Merck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory read more
- Baxter expands successful launch of AMIA with SHARESOURCE to include Canada
- Canadian home dialysis patients to gain access to therapy with two-way connectivity with healthcare team
- AMIA operator-friendly features designed so more patients can manage therapy at home
MISSISSAUGA, ONTARIO, June 29, 2016 – Baxter International Inc. (NYSE: BAX) is expanding the introduction of its AMIA Automated Peritoneal Dialysis (APD) System with the SHARESOURCE Connectivity Platform to Canada with the announcement that Health Canada recently approved the system. The AMIA APD and SHARESOURCE system is the first APD device cleared in the United States and Canada to include patient-centric features such as voice guidance, a touchscreen control panel and two-way telemedicine capabilities for remote patient management. read more
Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results | Pfizer: One of the world’s premier biopharmaceutical companies SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular eventsPfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among adults at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of a highly effective statin. read more
Medline and Medic Management Group Launch New GPO Distribution PartnershipNearly 3,000 physicians to receive meaningful cost savings on essential medical supplies
MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence AwardsALEXANDRIA, Va.--(EON: Enhanced Online News)–MPR is proud to announce Innovative Trauma Care’s iTClamp® device was named the gold winner in the ‘Critical Care and Emergency Medicine Products’ category of the 2016 Medical Design Excellence Awards. The winners were announced at a ceremony in NYC in conjunction with the Medical Device & Manufacturing East conference.
Elekta introduces Venezia, a new option for treating advanced stage cervical cancer at World Congress of Brachytherapy
Offers clinicians an intuitive and versatile tool for optimizing patient care
At the World Congress of Brachytherapy, June 27 – 29 in San Francisco, Elekta (booth #401) will introduce Venezia, a new option for treating advanced stage cervical cancer. Venezia is an advanced gynecological applicator that provides clinicians with improved access to stage IIIA, IIIB and IVA tumors in the cervix, parametrium and vaginal extensions.
Venezia allows clinicians to treat advanced stage cervical tumors that previously required specialized techniques such as free-hand needle placement. The applicator offers an easy way to reach tumors through a combination of straight and oblique needles with reproducible and consistent needle placement. read more